Close

Drug Research

Takeda and Frazier Healthcare Announce Collaboration to Launch HilleVax to Develop Clinical Stage Norovirus Vaccine Candidate

Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and...

GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and...

Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery

Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MOLCURE Inc., announced they generated potent, binding antibodies to an undisclosed oncology target for Twist’s internal pipeline...

Abzena and BioXpress Therapeutics announce partnership to support the development and manufacture of biosimilars for global customers

Abzena, a Global Partner Research Organization for integrated bench to patient solutions for biologics and bioconjugates, and BioXpress Therapeutics, a world-class leading developer of high quality, monoclonal antibody (mAb) biosimilar therapeutics have announced their partnership to support biosimilar development...

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC Protein Degrader ARV-471

Arvinas, Inc. and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is...

Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy

Samsung Biologics, one of the world’s leading contract development and manufacturing organization (CDMO), signed a strategic partnership agreement with Kineta, Inc., a clinical-stage biotech company developing novel immunotherapies in oncology. Samsung Biologics will provide end-to-end CDMO service from cell...

LGM Pharma launches standalone analytical services for drug developers and manufacturers

LGM Pharma announced the launch of its new Analytical Services offering that provides analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies. The company, which already conducts analytical services as part of its integrated contract...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read